Journal of surgical oncology · 2004
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aihara Tomohiko, Munakata Satoru, Morino Hideo, Takatsuka Yuichi
Аннотация
BACKGROUND AND OBJECTIVES: Sentinel node biopsy (SNB) is used for evaluation of axillary lymph node status of patients with breast cancer. The usefulness of SNB after neoadjuvant chemotherapy is not established. In addition, SNB after endocrine therapy has rarely been evaluated. We assessed the feasibility of dye guided SNB after neoadjuvant endocrine therapy in comparison with those of SNB after chemotherapy.
METHODS: A total of 36 patients subjected to SNB after endocrine therapy alone (n = 16) (tamoxifen, anastrozole or combination of goserelin and tamoxifen) or after chemotherapy (n = 20) (anthracycline and/or taxane) were included. SNB was performed with indigocarmine dye prior to the wide resection of the tumor or mastectomy.
RESULTS: Sentinel nodes were successfully identified in 100% (16/16) of patients after endocrine therapy and in 85% (17/20) of patients after chemotherapy. The mean number of harvested sentinel nodes was 2.2 after endocrine therapy and 1.8 after chemotherapy. There was no false negative case after endocrine therapy and there was one false negative case after chemotherapy (8% of overall false negative rate).
CONCLUSIONS: SNB seemed feasible and accurate after neoadjuvant endocrine therapy in patients with breast cancer.
METHODS: A total of 36 patients subjected to SNB after endocrine therapy alone (n = 16) (tamoxifen, anastrozole or combination of goserelin and tamoxifen) or after chemotherapy (n = 20) (anthracycline and/or taxane) were included. SNB was performed with indigocarmine dye prior to the wide resection of the tumor or mastectomy.
RESULTS: Sentinel nodes were successfully identified in 100% (16/16) of patients after endocrine therapy and in 85% (17/20) of patients after chemotherapy. The mean number of harvested sentinel nodes was 2.2 after endocrine therapy and 1.8 after chemotherapy. There was no false negative case after endocrine therapy and there was one false negative case after chemotherapy (8% of overall false negative rate).
CONCLUSIONS: SNB seemed feasible and accurate after neoadjuvant endocrine therapy in patients with breast cancer.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAnastrozoleAnthracyclinesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAxillaBreast NeoplasmsBridged-Ring CompoundsFeasibility StudiesFemaleGoserelinHumansLymph NodesMiddle AgedNeoadjuvant TherapyNitrilesPilot ProjectsSentinel Lymph Node BiopsyTamoxifenTaxoidsTriazoles